Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the ...
Generex’s Ii-Key peptide vaccines for infectious disease and cancer have been studied in human clinical trials involving over 300 subjects in Phase I and Phase II clinical trials See publications at https://generex.com/covid-19 A Phase I …